ROLONTIS BLA filing is based on two large pivotal randomized controlled studies that met all primary and secondary endpoints. ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive

  Publication highlights pre-clinical and clinical activity of poziotinib in lung cancer patients with HER2 mutations and potential future applications using monotherapy and combinations in many different mutated cancers     HENDERSON, Nev. --(BUSINESS WIRE)--Oct.

  HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 25, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the 2019

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 6, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and beyond.

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 3, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at two upcoming

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 8, 2019-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2019 .

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 1, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the second quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on

Recent pre-clinical data supports development of poziotinib for osimertinib resistance, as well as atypical mutations. Three new cohorts are currently open to patient enrollment in the ZENITH20 trial: Cohort 5 (Expansion Study), Cohort 6 (EGFR osimertinib failures), and Cohort 7 (Atypical EGFR or

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 20, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the appointment of Elizabeth Czerepak to the Board of Directors. Ms.

Integrated efficacy and safety results in 643 patients were consistent with individual trial results (ADVANCE and RECOVER) The integrated data demonstrated that eflapegrastim provided an absolute risk reduction of severe neutropenia of 6.5% compared to pegfilgrastim in Cycle 1 HENDERSON, Nev.

HENDERSON, Nev. --(BUSINESS WIRE)--May 29, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York .

Enrollment of cohort 2 was completed six months ahead of schedule Cohort 2 had a target enrollment of 87 NSCLC patients with HER2 exon 20 insertion mutations Topline results from cohort 2 are expected in mid 2020 Topline results from cohort 1, which enrolled NSCLC patients with EGFR exon 20

HENDERSON, Nev. --(BUSINESS WIRE)--May 16, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the 20th Annual B. Riley FBR Investor Conference being held in Beverly Hills, CA.

Topline results in the previously treated EGFR cohort (cohort 1) of the poziotinib ZENITH20 trial are expected in Q4 2019. Integrated data from the two Phase 3 ROLONTIS ® (eflapegrastim) clinical trials will be presented in a poster session at the American Society of Clinical Oncology 2019 annual

The Focused Interferon Therapeutics (FIT) platform is a proprietary targeted antibody-interferon fusion technology with potential broad application in oncology This asset purchase adds two innovative early-stage drug candidates to Spectrum’s existing pipeline and advances the oncology strategy

HENDERSON, Nev. --(BUSINESS WIRE)--May 2, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 2, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today that an overview of the company's business strategy and development-stage programs will be given at the H.C. Wainwright Global Life Sciences Conference being held in London .

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 15, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that due to the U.S. Food and Drug Administration’s ( FDA ) request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 13, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 1, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA -approved hematology/oncology products to Acrotech Biopharma